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Background: Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease caused by the autoantibody
against granulocyte-macrophage colony stimulating factor (GM-CSF). The clinical course of aPAP is variable; in severe
cases, patients develop lethal respiratory failure due to pulmonary fibrosis. However, the pathogenesis of pulmonary
fibrosis in aPAP has never been delineated.
Case presentation: Here, we describe a rare case of aPAP that was subsequently complicated by microscopic
polyangiitis-related pulmonary fibrosis. The patient was a 75-year-old Japanese man diagnosed with aPAP based
on the crazy-paving appearance on high-resolution computed tomography (HRCT), “milky” appearance of
broncho-alveolar lavage fluid (BALF), and elevated serum levels of the anti-GM-CSF antibody. The patient was
followed-up without aPAP-specific treatment for 3 years. During this period, both hematuria and proteinuria appeared;
in addition, serum myeloperoxidase (MPO)-anti-neutrophil cytoplasmic antibody (ANCA) turned positive and increased
markedly. The second BAL performed one year after the diagnosis, showed that the “milky” appearance had resolved.
The HRCT showed that fibrotic changes had developed and that the crazy-paving appearance had disappeared.
These data suggest an association between pulmonary fibrosis that developed during the natural course of aPAP
and ANCA-related systemic vasculitis.
Conclusion: This is the first case report that suggests the existence of a pathogenetic relationship between
ANCA-associated systemic vasculitis and aPAP-related pulmonary fibrosis. The link between ANCA-associated
systemic vasculitis and aPAP-related pulmonary fibrosis requires further investigation.
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Autoimmune pulmonary alveolar proteinosis (aPAP), which
causes 90% of all PAP cases, is an autoimmune disease
caused by the presence of an autoantibody against
granulocyte-macrophage colony stimulating factor (GM-
CSF) [1]. The suppression of GM-CSF signaling by anti-
GM-CSF autoantibody disrupts the surfactant catabolism,
resulting in the accumulation of surfactant lipids and
proteins in pulmonary alveolar macrophages and alveoli.* Correspondence: hiroshi.kida@imed3.med.osaka-u.ac.jp
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unless otherwise stated.The clinical course of aPAP is variable. In the contem-
poraneous cohort of 223 Japanese aPAP patients, 3 pa-
tients (1.4%) were complicated by severe respiratory
failure due to pulmonary fibrosis [2]. And so far, there
have been, at least, 5 case reports, which highly sug-
gested the pathogenetic relationship between aPAP and
pulmonary fibrosis [3-7].
The pathogenesis of pulmonary fibrosis in aPAP is
unknown. It has been hypothesized that the retention
of lipoproteinaceous material in the alveoli, silica
exposure, and/or superimposed pulmonary infections
induces damage to cells lining the alveoli and causes
pulmonary fibrosis in aPAP patients [5]. In rats, thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vector leads to pulmonary fibrosis, suggesting an in-
conclusive relationship between GM-CSF therapy and
pulmonary fibrosis in patients with aPAP [8].
Anti-neutrophil cytoplasmic antibody (ANCA) is a sensi-
tive and specific marker for ANCA-associated systemic
vasculitis, as observed in granulomatosis with polyangiitis
(GPA), microscopic polyangiitis (MPA), “idiopathic” necro-
tizing crescentic glomerulonephritis and allergic granu-
lomatous angiitis [9]. In vitro and in vivo studies provide
compelling evidence that ANCA play a critical role in the
pathogenesis of ANCA-associated systemic vasculitis [10].
Pulmonary fibrosis due to alveolar capillaritis is a common
complication in ANCA-associated systemic vasculitis.
However, ANCA-related pulmonary fibrosis has never
been reported in association with aPAP.
Case presentation
A 75-year-old Japanese man, who self-identified as a
chronic smoker (30 pack-years), was referred to ourFigure 1 During the clinical course of aPAP in this patient, HRCT imag
opacity (arrows) and traction bronchiectasis (arrowheads). (A) Serum M
(circle), while the results of pulmonary function tests, including vital capacity (
Serum anti-GM-CSF antibody concentrations kept high and increased (B).hospital because of a cough, which had been continued
for 2 months, and an abnormal chest X-ray. He had no
significant past medical history. He was an owner of a
liquor shop and had no prior exposure to harmful dust.
The physical examination revealed fine crackles bilat-
erally over the lower lung. The laboratory findings
showed elevated levels of lactate dehydrogenase (376 U/
L; normal range, 120-242), Krebs von den Lungen-6
(17330 U/mL; normal range, 0-500), surfactant protein-
D (293.0 ng/mL; normal range, 0–110), carcinoem-
bryonic antigen (12 ng/mL; normal range, 0–5.0), and
CYFRA21.1 (cytokeratin-19 fragments) (26.5 ng/mL;
normal range, 0–20.0) in the serum. Serum antinuclear
antibody titer was 1:40 (normal range, <1:40), and
myeloperoxidase (MPO)-ANCA testing was negative.
The chest X-ray showed diffuse bilateral ground-glass
opacities, and high-resolution computed tomography
(HRCT) showed a crazy-paving appearance (Figure 1A).
Bronchoscopy was performed; the broncho-alveolar
lavage fluid (BALF) from the left lingura (B5) showed aes showed increased evidence of pulmonary fibrosis: reticular
PO-ANCA testing became positive and then increased significantly
VC, diamond) and CO diffusing capacity (DLCO, square), deteriorated.
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BALF was 320/μL. Differential cell count revealed 50%
alveolar macrophages, 36% lymphocytes, 12% neutro-
phils, 2% eosinophils. Pathological examination of a
transbronchial lung biopsy sample revealed periodic-
acid-Schiff stain-positive material along the alveolar
wall. After the serum anti-GM-CSF autoantibody con-
centration (28 μg/mL; normal range, <0.5) was con-
firmed and the comorbidity of hematological diseases,
such as chronic myelocytic leukemia, myelodysplastic
syndrome, or monoclonal gammopathy of undetermined
significance, were excluded, the patient was diagnosed
with aPAP.
Because the patient refused any specific treatment for
aPAP, including whole-lung lavage and GM-CSF inhal-
ation therapy, he was followed in the outpatient depart-
ment. Nine months later, his cough had worsened and
he began to experience dyspnea upon exertion, which
was classified using the modified Medical Research
Council Dyspnea Scale (mMRC) as grade 2. The chest
HRCT obtained at this visit showed that the crazy-
paving pattern had been replaced by fibrotic changes,
i.e., subpleural honeycombing and traction bronchiec-
tasis (Figure 1A). In contrast to the results obtained at
the time of diagnosis, the BALF was transparent, with-
out a “milky” appearance. Serum anti-GM-CSF auto-
antibody concentration was 23.5 μg/mL. Surprisingly,
serum MPO-ANCA testing was positive (134 IU/L) and
subsequently continued to rise (Figure 1B). In accord-
ance with the fibrotic changes seen on HRCT images,
the patient’s respiratory failure had worsened since
diagnosis (Figure 1B). The patient also showed signs of
hematuria and proteinuria. Although neither kidney
nor lung biopsies were performed because of the pa-
tient’s general condition, the findings presented above
met the most recent criteria for MPA [11]. Because the
patient refused steroid and immunosuppressant treat-
ment, he has been followed-up for MPA without any
specific therapy.
Many studies have shown that ANCA production is
key to the pathogenesis of MPA. ANCA is known to
activate neutrophils and allow their accumulation at the
endothelial portion of a vasculitic lesion [12]. ANCA is
also an excellent diagnostic marker of MPA with specifi-
city of 96.3-99.1% [13]. Based on these findings, the
European League against Rheumatism and the American
College of Rheumatology established new criteria that
emphasized serum ANCA in the diagnosis of MPA [14].
A new criterion of MPA, proposed by Watts, lays more
emphasis on the role of ANCA in MPA diagnosis, wherein
histopathological signs of vasculitis are not essential for
the diagnosis [11]. Our case met these criteria due to the
patient’s high level of MPO-ANCA and the associated
urinary findings.There are several reports of pulmonary fibrosis that
developed in patients with aPAP. In these cases, as in
ours, the features of PAP disappeared as pulmonary
fibrosis progressed [5,7]. As Luisetti et al. mentioned,
it is not possible for us to exclude that some subjects
diagnosed with diffuse fibrotic lung disease actually
represented the end-stage evolution of a previous pul-
monary alveolar proteinosis process [7]. If a patient’s
BALF or HRCT does not show a typical PAP appear-
ance at the time of admission, serum GM-CSF auto-
antibody is not usually measured. Thus, the link
between PAP and pulmonary fibrosis must be explored.
In this report, we suggest the role of ANCA-associated
systemic vasculitis in the pathogenesis of aPAP-related
pulmonary fibrosis. We sought to verify the existence
of ANCA-associated systemic vasculitis in patients with
aPAP-related pulmonary fibrosis, because in these cases,
steroids or immunosuppressants (including rituximab)
that are not usually used for the treatment of aPAP may
be effective for the treatment of pulmonary fibrosis [15].
There is one reported case of secondary PAP with high
levels of MPO-ANCA [16]. Further research will be neces-
sary to elucidate the link between aPAP and ANCA-
associated systemic vasculitis. Serum ANCA levels should
be examined in cases of aPAP complicated by pulmon-
ary fibrosis.
It is generally thought that autoimmune diseases are
induced by dysfunctional immunotolerance to self-
antigens due to genetic as well as environmental factors
[17]. Clinical evidence shows that the coexistence of auto-
immune diseases within an individual (i.e., polyautoimmu-
nity) is not uncommon, suggesting that these autoimmune
diseases have a common genetic or environmental root
[18]. It is also reported that aPAP sometimes accompanies
other systemic or organ-specific autoimmune diseases.
Seymour et al. reviewed 410 cases of PAP and reported
seven cases (1.7%) with coexisting autoimmune disor-
ders or positive autoimmune serology (rheumatoid arth-
ritis, two cases; anti-smooth muscle antibody positive, two
cases; multiple sclerosis, one case; IgA nephropathy, one
case; and celiac disease, one case) [19]. Inoue et al.
reported three cases among 212 patients with aPAP that
were complicated by other autoimmune diseases including
polymyalgia rheumatica, GPA, and autoimmune hemolytic
anemia [2]. Whether the coexistence of aPAP and ANCA-
associated systemic vasculitis in our case was anecdotal
or due to shared underlying mechanisms remains to be
elucidated. However, it is known that air pollution and/
or infections sometimes overwhelm immunotolerance
to MPO, even in healthy individuals [20]. Owing to their
genetic tendency toward autoimmune disease and the
altered immunologic milieu in their lungs, aPAP patients
might be prone to developing an autoimmune reaction to
MPO, triggered by an unknown environmental factor.
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Previous research has not succeeded in explaining why
pulmonary fibrosis occurs in patients with aPAP, or
how we should treat this complication, which is often
associated with a poor prognosis. This is the first case
report to suggest a pathogenetic relationship between
ANCA-associated systemic vasculitis and aPAP-related
pulmonary fibrosis. The link between ANCA-associated
systemic vasculitis and aPAP-related pulmonary fibrosis
must be explored with further research.
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